NASH Highlights


31 December 2017


Seeking patients with silent liver disease that affects millions  [Reading Eagle - AP]

As mentioned to this story in AP, there is a great need for patients to participate in clinical trials for the approval of NASH drugs. Another point stated in this story was that the awareness of NASH remains especially low among primary doctors who don't know to look for signs. Let's look forward to more awareness, knowledge sharing and collaborations, to fight this silent disease.

12 December 2017


Will AI Be Part of Your Health-care Team? [WebMD]

"I think this [artificial intelligence] is exciting, and will likely be the key element for enhancing the efficiency and quality of pathologists' diagnoses," said researcher Babak Ehteshami Bejnordi, of Radboud University Medical Center in the Netherlands.

3 December 2017


Desire to help others led donor to liver recipient [Indiana Gazette]

Peggy was battling for her life after being diagnosed with nonalcoholic steatohepatitis, or NASH. She was indeed lucky to have met a donor, who was the perfect match. Liver transplant is the only real option for NASH. Hence, around the world, patients are placing their hopes for effective drugs to treat this disease.

26 November 2017


Coffee makes for a healthy liver, says board of experts [Medical News Today]

A commentary in the Mendon Journal. Fancy a cuppa, anyone?

24 November 2017


Fatty liver linked to shrinking brain

(Report from Reuters Health) Fatty liver disease that is not related to excess drinking is associated with greater brain shrinkage than normally happens with age, researchers say.
"Liver fat may have a direct association with brain ageing." - Lead author, Galit Weinstein, School of Public Health, University of Haifa, Israel.

21 November 2017


34 million euro project to develop better test for liver disease

A pioneering European research project aims to lead to new diagnostic tests to assess patients with non-alcoholic fatty liver disease and identify those most at risk of developing problems. 

2 November 2017


Why you might get liver disease even if you're not much of a drinker

“To get an idea of the extent of the issue, think of it like this: If you’re hanging out with two friends, it’s very likely one of you has a fatty liver problem,” says Wayne Eskridge, CEO of the nonprofit Fatty Liver Foundation. “It is the coming epidemic of our time because, although medicine is making progress against most other major diseases, there is no treatment for fatty liver disease.”

24 October 2017


Experts raise red flag over fatty liver disease

Rinella noted that the number of liver transplants owing to advanced NASH has risen 68% in the past decade, while the number of available organs has only risen 11%. And the number of people with NASH on transplant waiting lists is expected to grow 55.4% by 2030, she added.

24 October 2017


Call to Action: Kids need fatty liver research, diagnostics, treatment

With up to 10% of children worldwide diagnosed with nonalcoholic fatty liver disease and even nonalcoholic steatohepatitis, pediatric hepatologists face an unmet need for medical treatment and non-invasive diagnostics, according to a presenter at The Liver Meeting 2017.

18 October 2017


A common herbal medicine may cause liver cancer mutations

Extracts taken from plants of the genus Aristolochia, which are used in traditional Chinese medicine to treat a wide range of conditions, may be responsible for many liver cancers in Asia.

17 October 2017


Can Taurine and polyphenols help treat fatty liver disease?

Taurine, an amino acid, is believed to have effects on levels of blood glucose, lipids, and liver transaminases. Polyphenols are the natural compounds found in tea and are often used as natural antioxidants. The combination of taurine and tea polyphenols might reveal a possible treatment in addition to changes in diet and lifestyle for fatty liver disease, specifically NASH.

10 October 2017


Liver disease risk may be heightened by gastric acid drugs

Researchers found that proton pump inhibitors, which are drugs used to reduce gastric acid, could promote the growth of a type of bacteria associated with chronic liver diseases.

3 October 2017


NASH: Pointers for Pharma from the Patient's Perspective

The disease was first identified in the 1980s. Since then, its prevalence has grown rapidly in line with that of NAFLD, now one of the most common liver diseases worldwide. These trends reflect a growing epidemic of type 2 diabetes and obesity worldwide. One recent meta-analysis found the global prevalence of NAFLD to be around 25%, while the global prevalence of NASH is estimated at 3-5%.

22 September 2017


Combinations of PACS and AI helps uncover what radiologists sometimes miss

“A key benefit is that the AI software searches certain imaging studies for several specific conditions,” Gaskin explained. “It calculates liver density from a CT chest or abdomen study to detect a fatty liver, identifies emphysema by detecting levels of trapped air in the lungs from a CT chest study, and determines levels of coronary calcium from non-contrast CT chest studies, in addition to assessing bone density.”

13 September 2017


Do you have diabetes, liver disease? Watch out for CVD

A study analyzing the medical data of more than 133,000 people shows that those with diabetes and a medical history of non-alcoholic fatty liver disease have a significantly higher risk of cardiovascular disease and mortality. 


24 August 2017

Demand for liver transplant for NASH set to continue rising

Given population obesity trends, the increase in the demand for liver transplantation (LT) for nonalcoholic steatohepatitis (NASH) noted since 2000 is expected to continue, according to a study published online Aug. 17 in Hepatology.


21 August 2017

NASH Biomarkers Market Analysis by Type, End-use and Segment Forecasts, 2014 - 2025

The global non-alcoholic steatohepatitis (NASH) biomarkers market is expected to reach USD 2.09 billion by 2025, according to a new report by Grand View Research, Inc.


21 August 2017

Low thyroid function predicts NASH, fibrosis in patients with fatty liver

“The prevalence of NASH and advanced fibrosis associated with [thyroid-stimulating hormone levels] was significantly higher in subjects with subclinical hypothyroidism than in those with normal thyroid function,” the researchers wrote.


18 August 2017


Organ crosstalk: Fatty liver can cause damage to other organs

According to the article, fatty liver increases the risk of chronic liver diseases (liver cirrhosis and liver cancer), as well as type 2 diabetes and cardiovascular diseases. How this happens is that the fatty liver increasingly produces glucose, unfavorable fats and proteins, such as the hepatokine fetuin-A, all of which it releases into the bloodstream and enters other organs, triggering adverse reactions.


15 August 2017


Fibrosis, not NASH, predicts death, disease in fatty liver

Nonalcoholic steatohepatitis did not increase the risk for liver-related morbidity, overall mortality or the time to development of severe liver disease in patients with nonalcoholic fatty liver disease, according to recently published data. However, fibrosis stage can be used as a significant marker.


26 July 2017

NASH linked to early markers of hypertrophy

Whether diastolic dysfunction similarly portends a risk of future [heart failure] among patients with NAFLD and/or NASH remains unknown, and we eagerly await well-designed, prospective studies to characterize this relationship.


19 July 2017


AASLD releases NAFLD practice guides for screening, treatment

“There is a paucity of data regarding the incidence of NAFLD in the general population. ... The incidence rates for NAFLD in the general population of Western countries are even less commonly reported [than those in Asian countries],” the researchers wrote.

In contrast to the incidence data, there is a significantly higher number of publications describing the prevalence of NAFLD in the general population.


6 July 2017

Millions of people are living with a silent disease they've likely never heard of

... And NASH is set to surpass hepatitis as the biggest reason for liver transplants by 2020. That is seriously alarming!


5 July 2017

NASH: KOL Insight

Key takeaway from experts on current study designs and endpoints, and the challenges facing novel therapies such as long-term safety, cost and diagnosis.


3 July 2017

Fatty liver disease can be a silent killer

According to a report in Singapore's The New Paper (TNP), Non-alcoholic fatty liver disease - which can lead to liver cirrhosis or cancer - is on the rise in Singapore.


30 June 2017


AASLD Foundation announces $3.34 Million in liver disease research and career development funding

“Liver disease continues to be a critical healthcare issue in the United States and internationally. Despite recent strides and successes in the treatment of many liver diseases, AASLD Foundation understands there is still much work to be done and more funding must be made available to those interested in hepatology.” - Bruce R. Bacon, MD, FAASLD, AASLD Foundation Chair.

26 June 2017

Looking for clues for dangerous fatty liver disease

"When you combine the fact that the natural history of the disease is unclear; it's difficulty to diagnose, treat and stage it; and there's no FDA-approved medicine, it becomes a huge issue." - Dr. Jaideep Behari, associate professor of medicine at the University of Pittsburgh and director of Fatty Liver Clinic.

Click on the headline to read the article on fatty liver disease and nonalcoholic steatohepatitis (NASH).

Story by Medical Xpress


19 June 2017

First-degree relatives of patients with NAFLD-cirrhosis at risk for advanced fibrosis

"According to researchers, first-degree relatives of patients with nonalcoholic fatty liver disease and cirrhosis have a 12-times higher risk for developing advanced fibrosis compared with first-degree relatives without NAFLD."

Story by Healio


13 June 2017

Non-Alcoholic Fatty Liver Disease (NAFLD) Forecast in 11 Major Markets 2017-2027

Report by Research and Markets.


6 June 2017

New study indicates that drinking even a few cups a day may prevent hardening of the liver, reports the Journal of Hepatology. So don't forget that cuppa, everyone!



1 June 2017

EMA consults on regulatory requirements for chronic liver disease drugs

“Specifically, EMA says the diseases pose a significant challenge for drugmakers to study, as all three have a long progression and symptoms that are either unspecific or non-predictive of long-term outcomes. Furthermore, EMA says the use of "hard" clinical outcomes like liver transplantation or death raise feasibility issues for studies, and the need for repeated liver biopsies deters patients from enrolling in studies and increases risk.

Because of these challenges, EMA says there is a strong need for a validated surrogate endpoint to reduce the need for biopsies.”

Story by Regulatory Affairs Professional Society


31 May 2017

Commissioner Carlos Moedas on the importance of research and innovation in fighting NAFLD and NASH

During the first European- NAFLD-NASH Policy Summit last month, Carlos Moedas, European Commissioner for Research, Science and Innovation, stressed the "need to scale up efforts in research and innovation [to] develop simple, cost-effective and non-invasive tests" that will allow to "improve guidance to member states on primary care and better management".

Read more and watch this video to hear the full message.

Story by the European Liver Patients Association (ELPA)

Note: Organised by the ELPA, the first European- NAFLD-NASH Policy Summit took place on May 31 this year. The event addressed potential measures to reduce the burden of NAFLD/NASH.